cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc24z8yc
title: CCDC 1995313: Experimental Crystal Structure Determination

description: Related Article: Alen Bjelopetrović, Dajana Barišić, Zrinka Duvnjak, Ivan Džajić, Marina Juribašić Kulcsár, Ivan Halasz, Manuel Martínez, Ana Budimir, Darko Babić, Manda Ćurić|2020|Inorg.Chem.|59|17123|doi:10.1021/acs.inorgchem.0c02418
DOI: 10.5517/ccdc.csd.cc25925r
title: CCDC 2004713: Experimental Crystal Structure Determination

description: Related Article: Arnab Mandal, Amit Adhikary, Abani Sarkar, Debasis Das|2020|Inorg.Chem.|59|17758|doi:10.1021/acs.inorgchem.0c02985
DOI: 10.25919/chse-kx42
title: Parkes observations for project P1050 semester 2020OCTS_01

description: This is a request for observing time for the timing campaign of new pulsar discoveries and follow-up of expected new potential pulsars from the re-processing of the low-latitude Galactic plane section of the HTRU survey (P630). We have now completed the first pass re-processing of the 62 % of the survey with GPU based coherent acceleration search and template bank search pipelines, and have discovered 51 previously unknown pulsars. Interesting science can usually only be derived from a new pulsar after confirmation and a follow-up timing campaign is carried out. One year of initial timing is the minimum timespan required to fully characterise any newly-discovered pulsars, essential for deriving pulsar parameters such as the characteristic age, magnetic field strength, spin-down rate, as well as to detect any unexpected behaviour of the pulsar which might result from emission instabilities. This timing project is necessary for following up on any interesting pulsar systems discovered from the HTRU Galactic plane survey. Since all of the pulsars on the observing list here have been confirmed in the current 2020APRS semester, the follow-up timing will produce completely new and exciting results. In addition, this timing project will enable a large-scale examination of the Galactic plane pulsar population, exploring the true boundaries of pulsar parameter space in the galactic plane.
DOI: 10.5281/zenodo.4400671
title: Fungomeli_Maria_PhD_Thesis_Appendices_Dec_2020

description: Vegetation Data set used as Appendices in the PhD Thesis, December 2020.
DOI: 10.5281/zenodo.4400670
title: Fungomeli_Maria_PhD_Thesis_Appendices_Dec_2020

description: Vegetation Data set used as Appendices in the PhD Thesis, December 2020.
DOI: 10.6084/m9.figshare.12130980.v65
title: MOOD Maps of Google community mobility change during the COVID-19 outbreak

description: The MOOD project (MOnitoring Outbreak events for Disease surveillance in a data science context. H2020) has geo-referenced the data Google has published as a series of PDF files presenting reports on national and subnational human mobility levels relative to a baseline data of late January 2020. The details and the PDF files can be found at https://www.google.com/covid19/mobility/.<br>More detail on these files can be found at https://www.moodspatialdata.com/humanmobilityforcovid19 <br>The first set of data were released on April 2 2020 and have been revised weekly since then. The maps now utilise the CSV data released by Google. Please note that the maps figures use a mean of the previous three days, while the Google PDFs use a single days data so there will be differences between values in our maps when compare to the Google PDFs.<br>The authors have extracted the majority of these data into a series of excel spreadsheets. Each worksheet provides the data for % change in numbers of records at various types of location categories illustrated by: retail and recreation, grocery and pharmacy, parks and beaches, transit stations, workplaces and residential (columns f to K). A second set of columns calculates the difference of each value from the mean values for each category (columns L to P) Columns A to E contain geographical details. Column Q contains the names used to link to a mapping file.There are separate worksheets for the date of the data from each dated release (e.g. 2903, 0504 etc.) and separate worksheets calculating the changes between specific dates.<br>A second spreadsheet has been added calculating the 3 day moving mean of each day from the 15th of February. Each day is referenced by the Gregorian calendar day count. So day 48 = Feb 17th.<br>The maps (for EU & Global) display these data. We provide 600 dpi jpegs of the Global (“WD”) and European (“EU”) mapped values at the latest date available, for each of the mobility categories: retail and recreation (“retrec”) , grocery and pharmacy (“grocphar”) , parks (“parks”) , transit stations (“transit”), residential (“resid”) and workplaces (“work”). We also provide maps of the changes from the previous week (“ch”).<br>All data extracting and subsequent processing have been carried out by ERGO (Environmental Research Group Oxford) on behalf of the MOOD H2020 project. Data will be periodically updated. Additional maps can be obtained on request to the authors.
DOI: 10.5281/zenodo.4400785
title: Vegetation Data_Appendices_December_2020

description: Vegetation Data set_Appendices_Dec_2020
DOI: 10.5281/zenodo.4400784
title: Vegetation Data_Appendices_December_2020

description: Vegetation Data set_Appendices_Dec_2020
DOI: 10.25646/7797
title: Tagesdaten-CSV aus dem DIVI-Intensivregister

description: Die Tagesdaten-CSV entspricht einem Auszug der Daten des DIVI-Intensivregisters. Die Datei enthält eine Aggregation der aktuellsten Meldungen pro Landkreis. Es werden die aktuell gemeldeten Anzahlen der COVID-19 Intensivfälle sowie die gemeldeten intensivmedizinischen Behandlungskapazitäten angezeigt. Die Tagesdaten-CSV liefert dabei ausschließlich einen Blick auf die Daten gemäß dem Stand des betrachteten Tages. Die Daten sind im situationsbedingten Kontext aufbereitet, damit sind verschiedene Tagesdaten-CSVs u.U. nicht direkt miteinander vergleichbar. Die aktuellsten Meldungen werden im gewählten Betrachtungszeitfenster über alle Meldebereiche und Standorte aufsummiert. Weitere Informationen sind zu finden unter https://www.intensivregister.de/#/faq
DOI: 10.15468/utz3x5
title: Xerophilic Alopecosa sulzeri (Pavesi, 1873) (Araneae: Lycosidae) - a new wolf spider species in Poland

description: This dataset contains the digitized treatments in Plazi based on the original journal article Hajdamowicz, Izabela, Rozwa?ka, Robert, Sta?ska, Marzena, Rutkowski, Tomasz, Sienkiewicz, Pawe? (2020): Xerophilic Alopecosa sulzeri (Pavesi, 1873) (Araneae: Lycosidae) - a new wolf spider species in Poland. Zootaxa 4899 (1): 175-185, DOI: https://doi.org/10.11646/zootaxa.4899.1.9
DOI: 10.5281/zenodo.4384477
title: Dataset related to article "Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?"

description: This record contains raw data related to article “Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?" <strong>Background and purpose: </strong>Lymph nodes (LN) are common site of oligometastases and stereotactic body radiation therapy (SBRT) represents an effective ablative treatment. Aim of this study was to analyze a large cohort of nodal oligometastases treated with SBRT to identify impact on systemic therapy intensification, pattern of recurrence, and predictive factors. <strong>Materials and methods: </strong>We included patients with a maximum of 5 oligometastases. Concomitant treatments were allowed. Patients were treated with Volumetric Modulated Arc Therapy (VMAT) and end points were local control of treated metastases (LC), locoregional nodal control (LRNC), distant nodal control (DNC), distant metastases free survival (DMFS), overall survival (OS) and freedom from treatment intensification (FFTI). <strong>Results: </strong>418 LN were treated in 278 patients with 327 SBRT treatments. Patients were more commonly affected by colorectal (20.9%) and prostate cancer (17.99%). Most represented schedule was 45 Gy in 6 fractions, with a median BED10 of 78.75 Gy. After median follow-up of 15.1 months, LC at 1 and 2 years were 87.2% and 76.8%, respectively. Prostate primary tumor, small volume, oligorecurrence, and BED10 ≥75 Gy were associated with higher LC. One and 2 years FFTI were 82.8% and 74.5%; in patients reporting intensification of systemic therapy, median time was 8.43 months, while for patients who repeated SBRT, median FFTI was 14.6 months. Rates of LRNC at 1 and 2 years were 70.9% and 57.6%, and DNC were 82.0% and 77.9%. <strong>Conclusion: </strong>With the present analysis, we confirmed on a large cohort the benefit from SBRT on lymph node oligometastases in multidisciplinary management. Combination of SBRT with new systemic therapies, including immunotherapy and targeted therapy, should be investigated to reduce the risk of progression out of the field of irradiation.
DOI: 10.5281/zenodo.4384476
title: Dataset related to article "Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?"

description: This record contains raw data related to article “Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?" <strong>Background and purpose: </strong>Lymph nodes (LN) are common site of oligometastases and stereotactic body radiation therapy (SBRT) represents an effective ablative treatment. Aim of this study was to analyze a large cohort of nodal oligometastases treated with SBRT to identify impact on systemic therapy intensification, pattern of recurrence, and predictive factors. <strong>Materials and methods: </strong>We included patients with a maximum of 5 oligometastases. Concomitant treatments were allowed. Patients were treated with Volumetric Modulated Arc Therapy (VMAT) and end points were local control of treated metastases (LC), locoregional nodal control (LRNC), distant nodal control (DNC), distant metastases free survival (DMFS), overall survival (OS) and freedom from treatment intensification (FFTI). <strong>Results: </strong>418 LN were treated in 278 patients with 327 SBRT treatments. Patients were more commonly affected by colorectal (20.9%) and prostate cancer (17.99%). Most represented schedule was 45 Gy in 6 fractions, with a median BED10 of 78.75 Gy. After median follow-up of 15.1 months, LC at 1 and 2 years were 87.2% and 76.8%, respectively. Prostate primary tumor, small volume, oligorecurrence, and BED10 ≥75 Gy were associated with higher LC. One and 2 years FFTI were 82.8% and 74.5%; in patients reporting intensification of systemic therapy, median time was 8.43 months, while for patients who repeated SBRT, median FFTI was 14.6 months. Rates of LRNC at 1 and 2 years were 70.9% and 57.6%, and DNC were 82.0% and 77.9%. <strong>Conclusion: </strong>With the present analysis, we confirmed on a large cohort the benefit from SBRT on lymph node oligometastases in multidisciplinary management. Combination of SBRT with new systemic therapies, including immunotherapy and targeted therapy, should be investigated to reduce the risk of progression out of the field of irradiation.
DOI: 10.5281/zenodo.4384553
title: Dataset related to article "Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity"

description: This record contains raw data related to article “Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity" <strong>Introduction: </strong>Stereotactic body radiation therapy (SBRT) is considered an effective and safe treatment in patients with low- and intermediate-risk prostate cancer (PC). However, due to a lack of long-term follow-up and late toxicity data, this treatment is not universally accepted. The present study aimed to evaluate outcome and early and late toxicity in a cohort of patients with low- and intermediate-risk PC treated prospectively with linear accelerator (linac)-based SBRT. <strong>Patients and methods: </strong>Patients with low- or intermediate-risk (NCCN criteria) PC were included. All patients received linac-based SBRT to 35 Gy in 5 fractions delivered on alternate days. Endpoints were toxicity, biochemical relapse-free survival (BRFS), metastatic progression-free survival (mPFS), and overall survival (OS). <strong>Results: </strong>From 2012 to 2018, 178 patients were treated. Median baseline prostate-specific antigen (iPSA) was 6.37 ng/ml (range 1.78-20). Previous transurethral resection of the prostate (TURP) was present in 23 (12.9%) patients. Median follow-up was 58.9 months (range 9.7-89.9). BRFS rates at 1, 3, and 5 years were 98.3 (95% confidence interval, CI, 94.7-99.4%), 94.4 (95%CI 89.4-97), and 91.6% (95%CI 85.4-95.2), respectively. In univariate analysis, performance status (PS), iPSA, and nadir PSA (nPSA) were correlated with BRFS. In multivariable analysis iPSA and nPSA remained significant. BRFS rates at 5 years were 94.9% (95%CI 86.8-98) for International Society of Urological Pathology (ISUP) grade group 1, 93.2% (95%CI 80.5-97.7) for ISUP group 2, and 74.8% (95%CI 47.1-89.5) for ISUP group 3. At 1, 3, and 5 years, mPFS rates were 98.8 (95%CI 95.5-99.7), 96.2 (95%CI 91.9-98.3), and 92.9% (95%CI 87.2-96.2), respectively; OS rates were 100, 97.2 (95%CI 92.9-98.9), and 95.1% (95%CI 90-97.6), respectively. One (0.56%) case of grade 3 acute genitourinary (GU), one case of acute gastrointestinal (GI), and one case of grade 3 late GU toxicity were observed. GI toxicity positively correlated with prostate volume. <strong>Conclusion: </strong>At long-term follow-up, linac-based SBRT continues to be a valid option for the management localized PC. Biochemical control remains high at 5 years, albeit with some concerns regarding the optimal schedule for unfavorable intermediate-risk PC. Considering the excellent prognosis, patient selection is crucial for prevention of severe late toxicity.
DOI: 10.5281/zenodo.4384552
title: Dataset related to article "Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity"

description: This record contains raw data related to article “Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity" <strong>Introduction: </strong>Stereotactic body radiation therapy (SBRT) is considered an effective and safe treatment in patients with low- and intermediate-risk prostate cancer (PC). However, due to a lack of long-term follow-up and late toxicity data, this treatment is not universally accepted. The present study aimed to evaluate outcome and early and late toxicity in a cohort of patients with low- and intermediate-risk PC treated prospectively with linear accelerator (linac)-based SBRT. <strong>Patients and methods: </strong>Patients with low- or intermediate-risk (NCCN criteria) PC were included. All patients received linac-based SBRT to 35 Gy in 5 fractions delivered on alternate days. Endpoints were toxicity, biochemical relapse-free survival (BRFS), metastatic progression-free survival (mPFS), and overall survival (OS). <strong>Results: </strong>From 2012 to 2018, 178 patients were treated. Median baseline prostate-specific antigen (iPSA) was 6.37 ng/ml (range 1.78-20). Previous transurethral resection of the prostate (TURP) was present in 23 (12.9%) patients. Median follow-up was 58.9 months (range 9.7-89.9). BRFS rates at 1, 3, and 5 years were 98.3 (95% confidence interval, CI, 94.7-99.4%), 94.4 (95%CI 89.4-97), and 91.6% (95%CI 85.4-95.2), respectively. In univariate analysis, performance status (PS), iPSA, and nadir PSA (nPSA) were correlated with BRFS. In multivariable analysis iPSA and nPSA remained significant. BRFS rates at 5 years were 94.9% (95%CI 86.8-98) for International Society of Urological Pathology (ISUP) grade group 1, 93.2% (95%CI 80.5-97.7) for ISUP group 2, and 74.8% (95%CI 47.1-89.5) for ISUP group 3. At 1, 3, and 5 years, mPFS rates were 98.8 (95%CI 95.5-99.7), 96.2 (95%CI 91.9-98.3), and 92.9% (95%CI 87.2-96.2), respectively; OS rates were 100, 97.2 (95%CI 92.9-98.9), and 95.1% (95%CI 90-97.6), respectively. One (0.56%) case of grade 3 acute genitourinary (GU), one case of acute gastrointestinal (GI), and one case of grade 3 late GU toxicity were observed. GI toxicity positively correlated with prostate volume. <strong>Conclusion: </strong>At long-term follow-up, linac-based SBRT continues to be a valid option for the management localized PC. Biochemical control remains high at 5 years, albeit with some concerns regarding the optimal schedule for unfavorable intermediate-risk PC. Considering the excellent prognosis, patient selection is crucial for prevention of severe late toxicity.
DOI: 10.5517/ccdc.csd.cc21xwf9
title: CCDC 1904591: Experimental Crystal Structure Determination

description: Related Article: Kongqi Chen, Rongyuan Zhang, Zhiming Wang, Weijie Zhang, Ben Zhong Tang|2020|Adv.Opt.Mater.|8|1901433|doi:10.1002/adom.201901433
DOI: 10.5517/ccdc.csd.cc25sxfb
title: CCDC 2019942: Experimental Crystal Structure Determination

description: Related Article: Suzan El Anwar, Zdeňka Růžičková, Dmytro Bavol, Lukáš Fojt, Bohumír Grüner|2020|Inorg.Chem.|59|17430|doi:10.1021/acs.inorgchem.0c02719
DOI: 10.5517/ccdc.csd.cc25sxkg
title: CCDC 2019946: Experimental Crystal Structure Determination

description: Related Article: Suzan El Anwar, Zdeňka Růžičková, Dmytro Bavol, Lukáš Fojt, Bohumír Grüner|2020|Inorg.Chem.|59|17430|doi:10.1021/acs.inorgchem.0c02719
DOI: 10.5517/ccdc.csd.cc25sxlh
title: CCDC 2019947: Experimental Crystal Structure Determination

description: Related Article: Suzan El Anwar, Zdeňka Růžičková, Dmytro Bavol, Lukáš Fojt, Bohumír Grüner|2020|Inorg.Chem.|59|17430|doi:10.1021/acs.inorgchem.0c02719
DOI: 10.5517/ccdc.csd.cc25sxnk
title: CCDC 2019949: Experimental Crystal Structure Determination

description: Related Article: Suzan El Anwar, Zdeňka Růžičková, Dmytro Bavol, Lukáš Fojt, Bohumír Grüner|2020|Inorg.Chem.|59|17430|doi:10.1021/acs.inorgchem.0c02719
DOI: 10.5517/ccdc.csd.cc25tr6z
title: CCDC 2020741: Experimental Crystal Structure Determination

description: Related Article: Marianta Strinoiu, Mihai Răducă, Augustin M. Mădălan|2020|J.Coord.Chem.|73|2786|doi:10.1080/00958972.2020.1830977
DOI: 10.5281/zenodo.4384581
title: Dataset related to article "Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance"

description: This record contains raw data related to article “Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance" <strong>Introduction: </strong>In the context of metastatic breast cancer, dissemination to the liver is a frequent occurrence. We aimed to evaluate the outcome and toxicity of metastatic breast cancer with liver oligometastases treated with metastases-directed therapies (MDTs), including surgery, stereotactic body radiation therapy, or thermal ablation (radiofrequency or microwaves). <strong>Patients and methods: </strong>We included patients with diagnosis of 1 to 5 liver metastases. Selection criteria included also age &gt; 18 years; Eastern Cooperative Oncology Group performance status 0 to 2; absence of extra-hepatic disease or other controlled metastatic sites. Endpoints were liver progression-free survival (LPFS), progression-free survival (PFS), and overall survival. <strong>Results: </strong>A total of 72 patients were included. Previous local treatments were performed in 13 (18.1%) patients, whereas systemic therapy was used in 81.9% of cases. Treatment of choice was stereotactic body radiation therapy in 54 (75%) patients followed by surgery (13 patients; 18%) and thermal ablation (5 patients; 7%). With a median follow-up of 26.2 months, LPFS at 1 and 2 years was 52.4% and 38.8%, respectively. The number of metastases predicted LPFS (hazard ratio [HR], 1.70; P = .004). Rates of PFS were 38.7% and 22% at 1 and 2 years, respectively. Systemic therapy before MDT (HR, 2.89; P = .016) was correlated with PFS. Overall survival at 1 and 2 years was 95.5% and 76.9%, respectively. Human epidermal growth factor receptor 2 status correlated with survival (HR, 1.82; P = .010). <strong>Conclusion: </strong>Combination of systemic therapy with liver MDT in oligometastatic breast cancer results in durable disease control in a significant proportion of patients. Tumor biology, prior treatment, and extent of disease may be useful to guide the decision to add MDT to standard therapy.
DOI: 10.5281/zenodo.4384580
title: Dataset related to article "Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance"

description: This record contains raw data related to article “Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance" <strong>Introduction: </strong>In the context of metastatic breast cancer, dissemination to the liver is a frequent occurrence. We aimed to evaluate the outcome and toxicity of metastatic breast cancer with liver oligometastases treated with metastases-directed therapies (MDTs), including surgery, stereotactic body radiation therapy, or thermal ablation (radiofrequency or microwaves). <strong>Patients and methods: </strong>We included patients with diagnosis of 1 to 5 liver metastases. Selection criteria included also age &gt; 18 years; Eastern Cooperative Oncology Group performance status 0 to 2; absence of extra-hepatic disease or other controlled metastatic sites. Endpoints were liver progression-free survival (LPFS), progression-free survival (PFS), and overall survival. <strong>Results: </strong>A total of 72 patients were included. Previous local treatments were performed in 13 (18.1%) patients, whereas systemic therapy was used in 81.9% of cases. Treatment of choice was stereotactic body radiation therapy in 54 (75%) patients followed by surgery (13 patients; 18%) and thermal ablation (5 patients; 7%). With a median follow-up of 26.2 months, LPFS at 1 and 2 years was 52.4% and 38.8%, respectively. The number of metastases predicted LPFS (hazard ratio [HR], 1.70; P = .004). Rates of PFS were 38.7% and 22% at 1 and 2 years, respectively. Systemic therapy before MDT (HR, 2.89; P = .016) was correlated with PFS. Overall survival at 1 and 2 years was 95.5% and 76.9%, respectively. Human epidermal growth factor receptor 2 status correlated with survival (HR, 1.82; P = .010). <strong>Conclusion: </strong>Combination of systemic therapy with liver MDT in oligometastatic breast cancer results in durable disease control in a significant proportion of patients. Tumor biology, prior treatment, and extent of disease may be useful to guide the decision to add MDT to standard therapy.